Contact Us

Image representing a DEFINITY® professional team providing support and customer service to healthcare professionals interested in or using DEFINITY®

We are committed to the professional and patient communities we serve. In the spirit of this commitment, we invite ongoing feedback and dialogue.

Corporate Information:
Lantheus
201 Burlington Road, South Building
Bedford, MA 01730
Call Toll-Free: 1.800.362.2668

US Customer Service/Order DEFINITY®:
Monday-Friday 7:30 AM to 6:00 PM ET
Call Toll-Free: 1.800.299.3431
Fax: 1.978.671.8860
Fax Orders/POs: 1.978.436.7501

DEFINITY® Reimbursement Support:

Call Toll-Free: 833.429.5725833.429.5725
Email: reimbursement@lantheus.com

Lantheus cannot guarantee coverage or payment for products or procedures. Payer policies can vary widely and third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. For more specific information, contact your third-party payer directly in order to obtain up-to-date coverage, coding, and payment information.

Adverse Event and Product Quality Complaint Reports:

United States:
Call Toll-Free: 1.800.343.78511.800.343.7851
Press Option 2 for Adverse Events
Press Option 2 for Product Quality Complaints
Fax: 1.978.436.7296
Email: lantheussafety@lantheus.com

Outside the US:
Call Toll-Free: 1.978.667.95311.978.667.9531
Press Option 2 for Adverse Events
Press Option 2 for Product Quality Complaints
Fax: 1.978.436.7296
Email: lantheussafety@lantheus.com

Sales

If you would like a sales representative to contact you, please complete the form below.

Fields marked * are required.

First Name

Last Name

Specialty

Other Specialty

Role

Other Role

NPI Number

Facility

Zip

Telephone Number

Email Address

*I am interested in the following (check all that apply):

Contact with a sales representative

Product ordering information/customer service ordering information/customer service

Product information, patient education materials

Reimbursement information

Submission of Case Studies

Other

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

How we will use this information:

Lantheus Medical Imaging may collect data from you that you provide to us voluntarily, such as your name, postal address, email address, telephone number, and other personal information, such as your education level, professional affiliation, marital status, or personal medical information. If you provide us with these data, you agree that we may contact you to provide you with information we believe may be of interest to you.

Your information may be provided to other parties that Lantheus Medical Imaging is working with in order to help develop programs and provide services that may be of interest to you or for processing, mailing, and/or Internet-based delivery purposes. Within Lantheus Medical Imaging, data may be transferred to or accessed by authorized Lantheus Medical Imaging personnel in other countries.

If at any time you do not wish to be contacted by Lantheus Medical Imaging, or if you have any questions concerning our privacy practices, please feel free to contact us at bi.webadmin@lantheus.com.

Thank you for subscribing. We look forward to sharing exciting news about DEFINITY®.

INDICATION:

DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Assess all patients for the presence of any condition that precludes DEFINITY® administration.

Always have resuscitation equipment and trained personnel readily available.

CONTRAINDICATIONS:

Contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG).

WARNINGS AND PRECAUTIONS:

Serious Cardiopulmonary Reactions have occurred during or following administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias).

Serious Hypersensitivity Reactions have been observed during or shortly following administration including anaphylaxis, with manifestations that may include death. DEFINITY contains PEG and may increase risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG. Clinically assess patients for prior hypersensitivity reactions to products containing PEG. Monitor all patients for hypersensitivity reactions.

Systemic Embolization may occur in patients with a cardiac shunt. Assess patients with shunts for embolic phenomena following administration. DEFINITY is only for intravenous administration and must not be administered by intra-arterial injection.

There is a risk of Ventricular Arrhythmia Related to High Mechanical Index. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. The maximum recommended mechanical index for use with DEFINITY is 0.8 in adult patients and 0.3 in pediatric patients.

Acute Pain Episodes in Patients with Sickle Cell Disease (SCD) shortly following administration have been reported. Discontinue DEFINITY in SCD patients experiencing new or worsening pain.

ADVERSE REACTIONS:

The most common adverse reactions (≥0.5%) are headache, back/renal pain, flushing, nausea, chest pain, injection site reactions, and dizziness.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

Please see the accompanying full Prescribing Information and important safety information, including BOXED WARNING for serious cardiopulmonary reactions.

INDICATION AND IMPORTANT SAFETY INFORMATION